Development and content validation of a self-completed, electronic Pediatric Asthma Symptom Diary

Journal of Patient-Reported Outcomes

Table 5 Cognitive debriefing child participants characteristics

Characteristics	Philadelphia, PA, US Round 1 (n = 8)	Southfield, MI, US Round 2^a (n = 13)	Total (N = 21)
Age, years
Mean	8.5	8.0	8.2
Range	6–11	6–11	6–11
Sex, n (%)
Male	4 (50)	5 (38)	9 (43)
Female	4 (50)	8 (62)	12 (57)
Race, n (%)
Black	4 (50)	8 (62)	12 (57)
White	3 (38)	4 (31)	7 (33)
Other^b	1 (13)	1 (8)	2 (10)
Hispanic ethnicity, n (%)^c
Yes	1 (13)	0 (0)	1 (5)
No	7 (88)	13 (100)	20 (95)
Asthma severity, n (%)^d
Mild	2 (25)	3 (23)	5 (24)
Moderate	2 (25)	7 (54)	9 (43)
Severe	4 (50)	3 (23)	7 (33)
Reading skill level, n (%)
Can read alone	5 (63)	9 (69)	14 (67)
Can read but with some difficulty	2 (25)	2 (15)	4 (19)
Can only read a few words	1 (13)	2 (15)	3 (14)

ePASD electronic Pediatric Asthma Symptom Diary, MI Michigan, PA Pennsylvania, US United States
^aTwo of the 13 children (ages 6 [can read a few words] and 7 [can read but with difficulty]) participating in Round 2 interviews were unable to complete the cognitive interview for the ePASD nighttime diary; however, both of these children were able to successfully self-complete all of the ePASD questions on the tablet
^bRound 1 participant that selected “Other” for race specified mixed race of White/Black; Round 2 participant that selected “Other” for race specified mixed race of White/Asian
^cEthnicity was collected separately from race
^dAsthma severity levels defined based on Global Initiative for Asthma 2018 guidelines and child’s daily asthma controller medication use at screening as follows: Mild = low-dose inhaled corticosteroid (ICS) alone or leukotriene receptor antagonist (LTRA) alone; Moderate = low-dose ICS/ long-acting beta agonist (LABA), low-dose ICS + LTRA, medium-dose ICS alone or high-dose ICS alone; Severe = medium-dose ICS/LABA, medium-dose ICS + LTRA, high-dose ICS/LABA or high-dose ICS + LTRA